Methods: This was a retrospective analysis of data from 1,056 patients treated with SOF/VEL/VOX in the Phase 3 studies. Results: Overall, 38% of patients had cirrhosis, 70% had HCV RNA ≥800,000 IU/mL, 59% of the DAA-experienced patients had received an NS5A inhibitor-containing regimen, 20% of the DAA-naïve patients had prior treatment failure with pegylated interferon+ribavirin, 12% were ≥65 years old and 10% were black. SVR12 rates for the DAAnaïve SOF/VEL/VOX 8 week and DAA experienced

more »

... L/VOX 12 week subgroups were overall 95% & 97%; cirrhosis 94% and 95%; HCN RNA ≥800K 94% & 97%; age >65 96% and 99%; black 90% & 93% respectively. SVR12 rate for the DAA-naïve SOF/VEL/VOX 8 week prior PEG+RBV subgroup was 92%. SVR12 rate for the DAA experienced SOF/VEL/VOX 12 week prior NS5A Inhibitor subgroup was 96%. Conclusions: The POLARIS program enrolled a diverse patient population, including many with factors historically associated with treatment failure. Overall SVR12 rates for the DAA-naïve SOF/VEL/ VOX 8 week and DAA experienced SOF/VEL/VOX 12 week subgroups were 95% and 97% respectively and in those with cirrhosis were 94% and 95% respectively.